Project Grant R01CA293376
Award Date
8/12/24
Completion Date
7/31/29
Dollars Obligated
$949K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will support research to gain a comprehensive understanding of how adoptive T cell therapy (ACT) becomes dysfunctional within the tumor microenvironment of pancreatic cancer. The $169,344 award, running from 09/01/2024 to 08/31/2026, will leverage single-cell and spatial multi-omics analyses, computational modeling, and functional experiments to: 1) identify targetable T...
This $178,909 Project Grant awarded by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395) aims to accelerate the incorporation of immunotherapy and CD30-targeted cellular therapy into the treatment of Hodgkin lymphoma in children, adolescents, and young adults (AYAs). The award supports the principal investigator, Dr. Castellino, in her role as the Scientific Chair of the Hodgkin Lymphoma Committee in the Children's Oncology Group. Key...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $931,841 to The Leland Stanford Junior University to develop next-generation immunotherapies for pediatric cancers. The funding will support research to overcome the suppressive tumor microenvironment in pediatric solid tumors, optimize multi-specific CAR T cells, and explore in vivo gene delivery approaches to engineer immune populations without ex vivo manufacturing. This work aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $553,167 to The Washington University to conduct a Phase 1/2 clinical trial evaluating the safety, efficacy, and immunogenicity of a peptide vaccine (PEP-CMV) in combination with the checkpoint inhibitor nivolumab for the treatment of pediatric brain cancers. The trial will enroll patients aged 3-35 with newly diagnosed or recurrent diffuse midline glioma, high-grade glioma,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $172,013 to support the research work of a pediatric oncologist at the University of Colorado-Denver over the period of September 19, 2024 to August 31, 2029. The funded research aims to improve outcomes for children with acute lymphoblastic leukemia, particularly those who experience disease relapse, through the incorporation of novel targeted therapies into treatment regimens. The...
This $576,659 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to investigate tumor and host immune signatures associated with disparities in outcomes following GD2 immunotherapy for patients with high-risk neuroblastoma. The primary awardee, Emory University, is collaborating with sub-awardees Dana-Farber Cancer Institute and University of Florida to: Perform tumor-based single cell genomic, proteomic, and...